Gsa Capital Partners LLP Cytek Biosciences, Inc. Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2025
A detailed history of Gsa Capital Partners LLP transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 35,166 shares of CTKB stock, worth $142,070. This represents 0.01% of its overall portfolio holdings.
Number of Shares
35,166
Previous 79,062
55.52%
Holding current value
$142,070
Previous $317,000
62.15%
% of portfolio
0.01%
Previous 0.03%
Shares
5 transactions
Others Institutions Holding CTKB
# of Institutions
154Shares Held
73.9MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$69 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.77MShares$31.4 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD7.11MShares$28.7 Million0.72% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$26.9 Million0.93% of portfolio
-
State Street Corp Boston, MA4.17MShares$16.9 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $544M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...